省药监局相关处室负责人介绍，为切实提高药品监管能力，陕西药品监管"一体化"运行机制全面建 立运行，药品监管党政同责有效落实，省、市、县食品药品安全委员会机制健全，监管机构职能清晰、 运行顺畅。 2月5日，记者从省药监局获悉："十四五"以来，陕西药品监管系统持续深化监管改革，药品安全风 险防控得到有效落实，截至2025年底，陕西药品、疫苗、医疗器械、化妆品监管实现全覆盖。 在推进药品智慧监管建设方面，陕西已建成药品监管综合业务系统、陕西省疫苗（药品）追溯监管 系统、陕西省药品监管大数据中心，实现省、市、县三级药械化监管业务"一网通办"，疫苗、特殊药 品、血液制品、集采中选产品等重点药品实现全链条信息可追溯。全省药品监管各类信息集成共享，风 险识别、风险预警、风险处置实现闭环管理。（记者：周明） 为支持"两品一械"（药品、化妆品、医疗器械）产业高质量发展，"十四五"以来，陕西药监系统持 续深化审评审批制度改革，药械化创新取得显著成效。I类创新药甲磺酸普雷福韦片获批上市，实现陕 西I类创新药零的突破。5个三类医疗器械创新产品获批上市。2种化妆品新原料通过国家药监局备案。 196个品种药品通过或视同通过仿制药一致性评 ...

Core Viewpoint - Xintong Pharmaceutical Research Co., Ltd. has received approval for its IPO on the Sci-Tech Innovation Board, focusing on drug development for major liver diseases such as hepatitis B, metabolic dysfunction-related fatty liver disease, and liver cancer [1]. Company Overview - Established in May 2000, Xintong Pharmaceutical is a high-tech enterprise with over 20 years of experience in drug research and development, specifically targeting liver diseases [1]. - The company currently has eight core products for liver disease treatment, including one approved innovative drug and several others in various stages of clinical trials [1]. Financial Performance - Revenue figures for Xintong Pharmaceutical from 2022 to 2025 are as follows: - 2022: 1.10 million - 2023: 11.98 million - 2024: 30.19 million - 2025 (first half): 9.77 million [2][3]. - Net losses for the same periods are: - 2022: 53.87 million - 2023: 62.29 million - 2024: 79.36 million - 2025 (first half): 13.20 million [2][3]. Product Pipeline - The company has one Class 1 innovative drug, "Xinshi Mu®," which is the world's first targeted hepatitis B treatment developed using a liver-targeting technology platform, expected to be included in the national medical insurance directory by the end of 2025 [1]. Management Team - The company is led by Zhang Dengke, who serves as the Chairman and General Manager, and Jin Weili, who is the Chief Medical Officer [5]. - Zhang Dengke holds 46.45% of the company's shares directly and controls an additional 7.42% indirectly, totaling 53.86% [2][5]. Compensation - In 2024, Zhang Dengke received a salary of 1.015 million, while Jin Weili earned 4.021 million [6][7].

Group 1: Company Overview - Xian New Tong Pharmaceutical Research Co., Ltd. focuses on drug development for major liver diseases, including hepatitis B and liver cancer, with 8 core products in its pipeline [1] - Renben Co., Ltd. is the largest comprehensive bearing manufacturing group in China, with over 50,000 product specifications and a presence in over 70 countries [2] - Wolai Intelligent Technology Co., Ltd. specializes in smart manufacturing solutions for emerging industries, particularly in the automotive and semiconductor sectors [2] - Gaokai Technology is engaged in precision fluid control, with products used in semiconductor and consumer electronics industries [3] - Deep Blue Ocean Technology Co., Ltd. develops underwater robotics and solutions for various marine applications, holding 15 core technologies in the field [3] - Tongxin Medical Technology Co., Ltd. is an innovative medical device company focused on advanced heart failure treatments, with its first product approved in China and others in clinical trials [4] Group 2: Product Development and Market Position - New Tong Pharmaceutical has developed a first-class innovative drug, with one product already on the market and others in various clinical trial stages [1] - Renben has maintained the top position in domestic bearing production and sales for 12 consecutive years, nearing the capabilities of the top eight global competitors [2] - Wolai is recognized as a national key "little giant" enterprise, providing comprehensive smart manufacturing solutions [2] - Gaokai's product range includes flow control and precision dispensing systems, catering to the needs of intelligent manufacturing [3] - Deep Blue has established itself as a pioneer in the underwater robotics sector, with a complete product line and significant R&D investment [3] - Tongxin's CH-VAD system is the first fully magnetic levitation left ventricular assist device approved in China, with further innovations in the pipeline [4]

Core Viewpoint - New Tong Pharmaceutical has been accepted for IPO on the Shanghai Stock Exchange's Sci-Tech Innovation Board, focusing on drug development for major liver diseases such as hepatitis B and liver cancer, with a commitment to innovative drugs that meet clinical needs [1][2]. Group 1: IPO Process - This marks New Tong Pharmaceutical's second attempt at an IPO, having previously completed the entire listing process but ultimately failing to enter the issuance stage before the registration approval expired [2]. - The company submitted its IPO application in December 2021, received approval in April 2023, but could not proceed to issuance before the approval's expiration on April 25, 2024 [2]. Group 2: Product Pipeline and Revenue Dependence - Currently, New Tong Pharmaceutical has one approved innovative drug, Mesylate Prefofovir Tablets, which is expected to be commercially dependent in the short term [3]. - The company anticipates that Mesylate Prefofovir Tablets will be included in the national medical insurance directory by 2025 and will start sales at the insurance price in 2026 [3]. - The company faces risks related to potential price reductions of its products after market entry and the possibility of being removed from the medical insurance directory, which could significantly impact market share and revenue [3]. Group 3: Sales and Distribution Risks - New Tong Pharmaceutical employs an exclusive agency distribution model for Mesylate Prefofovir Tablets, leading to high customer concentration and reliance on a single distributor, KGI Securities [4]. - Revenue from KGI Securities and its subsidiaries accounted for 94.09% and 98.83% of total revenue in 2024 and the first half of 2025, respectively [4]. Group 4: Financial Performance - The company has reported negative net profits for several consecutive years, with a cumulative loss of 347 million yuan as of June 2025 [6]. - Revenue figures for recent years show a significant reliance on the single product, with total revenues of 976.70 million yuan in the first half of 2025, compared to 1,197.82 million yuan in 2023 [7]. - The company has a high R&D expense ratio, with R&D expenses exceeding revenue in recent years, indicating a focus on product development despite ongoing losses [7]. Group 5: Intellectual Property Risks - New Tong Pharmaceutical faces risks related to intellectual property, as some patents for its products have expired, potentially exposing them to generic competition [5]. - The company has applied for additional patents to enhance protection but still faces risks associated with the expiration of the five-year monitoring period for innovative drugs [5].